Summary
- Profile Type
- Research & Development Request
- POD Reference
- RDRSE20250226004
- Term of Validity
- 26 February 2025 - 26 February 2026
- Company's Country
- Sweden
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- Lithuania
- Malta
- Estonia
- Montenegro
- Austria
- United Kingdom
- Romania
- Latvia
- Switzerland
- Luxembourg
- Greece
- Croatia
- Germany
- Spain
- Finland
- Ireland
- Belgium
- Portugal
- Iceland
- Bulgaria
- Canada
- Poland
- Slovakia
- Hungary
- Czechia
- France
- Norway
- Netherlands
- Italy
- Slovenia
- Denmark
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- SME in Sweden specialized in the development of pharmaceutical products for the treatment of various disorders seeks collaborations in Eurostars and/or HORIZON EUROPE projects . Founded in 2014, the company offers expertise and have developed a drug delivery platform and are interested in collaborations within chronic pain/osteoarthritis (OA) and use of AI. Partners sought within clinical trials, preclinical testing, chemical synthesis, investigational drug product manufacturing or development.
- Full Description
-
Osteoarthritis (OA) is the most common form of arthritis and a leading cause of chronic disability world-wide. OA is a progressive disorder significantly impacting a patient's quality of life which affects their psychological and overall health. Pain is the predominant symptom, being related to both the motion and rest. Knee OA leads to increased mortality caused by cardiovascular diseases due to immobility and walking disability. Current available treatments are symptomatic, provide limited pain relief and are often associated with significant gastrointestinal, cardiac, or renal adverse effects.
The company is preparing a project to be submitted to the Eurostars funding programme for SMEs with cut off in September 2025. The company is experienced with the Eurostars program. The project will support future Phase I clinical trials to rigorously assess the safety and efficacy of our innovative approach of managing chronic pain in knee osteoarthritic patients. To this end the company intends to create a consortium and are looking for SME partners among manufacturing organisation (as a partner or subcontractor), clinical site(s), and analytical service (as a partner or subcontractor). The project is designed for 3 years
In addition, we have other projects focused on preclinical and clinical drug development that we would like to submit to Eurostars, Horizon Europe and other EU-funds. In particular, we are developing an advanced AI-driven platform aimed at accelerating the de novo design of target drugs using AI technologies, solving one of the main challenges of the effective use of AI: the lack of training sets for training models. The platform helps develop drugs for target proteins faster and easier, using only protein crystallographic structure and binding site data. To validate our platform, we are looking for partners with experience in chemical synthesis and preclinical testing.
The company has proprietary drug delivery platform for targeted drug delivery and is interested in participating as a partner to support the formulation development for targeted delivery of innovative medicine to the lungs or liver. The company is therefore looking for a leading partner that develops an innovative medicine that will benefit from targeted delivery to the lungs or liver. - Sustainable Development Goals
- Goal 3: Good Health and Well-being
Partner Sought
- Expected Role of a Partner
-
The SME is seeking consortium members and subcontractors to collaborate on Eurostars, Horizon Europe and other EU-funded research projects focused on preclinical and clinical drug development. The SME is open to participation in consortia both as lead partner and as co-applicant. The ideal partners include pharmaceutical companies, academic and research institutions, hospitals, clinical research centres, and regulatory bodies involved in drug discovery, preclinical and clinical testing.
A potential lead partner is developing an innovative medicine that would benefit from development of a formulation for targeted delivery to the lungs or liver.
A potential co-applicant for projects where the SME is the leading partner should specialize in clinical research, preclinical testing, chemical synthesis, investigational drug product manufacturing. - Type and Size of Partner
- SME 50 - 249
- SME <=10
- R&D Institution
- University
- Type of partnership
- Research and development cooperation agreement
Call details
- Framework program
- Access to finance
- Call title and identifier
-
Eureka Eurostars
- Coordinator required
-
Yes
- Deadline for EoI
- Deadline of the call
- Access to finance
Dissemination
- Technology keywords
- 01003003 - Artificial Intelligence (AI)
- 06001002 - Clinical Research, Trials
- 06001015 - Pharmaceutical Products / Drugs
- Market keywords
- 05003005 - Drug delivery and other equipment
- Targeted countries
- Lithuania
- Malta
- Estonia
- Montenegro
- Austria
- United Kingdom
- Romania
- Latvia
- Switzerland
- Luxembourg
- Greece
- Croatia
- Germany
- Spain
- Finland
- Ireland
- Belgium
- Portugal
- Iceland
- Bulgaria
- Canada
- Poland
- Slovakia
- Hungary
- Czechia
- France
- Norway
- Netherlands
- Italy
- Slovenia
- Denmark